Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of Adjuvant treatment of TNBC breast cancer with Toripalimab combined with neoadjuvant chemotherapy, including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the disease-free survival (DFS), Progression-Free-Survival (PFS ),and Objective Response Rate(ORR)

Trial Details

NCT ID
NCT06682195
Phase
PHASE2
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Neoadjuvant chemotherapy combined with Toripalimab
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306
  • Hangzhou, China|30.29365,120.16142
  • Hangzhou, China|30.29365,120.16142
  • Hangzhou, China|30.29365,120.16142
  • Harbin, China|45.75,126.65

Key Eligibility Criteria

  • Female patients aged 18-70 years old;
  • ECOG score is 0-1 points;
  • Histologically proven tumors \>1cm in diameter (T1c-3; N0-2; M0) invasive breast cancer;
  • All patients had triple negative breast cancer confirmed by histopathology;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →